.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
India's biotech sector growth has reached a major milestone. Specifically, the industry expanded from $10 billion to over $195 billion within a single decade. Union Minister Dr. Jitendra Singh announced this leap at BIRAC’s 14th Foundation Day. This rapid expansion reflects a robust 18% annual growth rate. Consequently, the sector now contributes approximately 4.8% to the national GDP.
Several factors have catalyzed this massive expansion since 2014. Firstly, the government established an enabling policy environment that prioritizes science and technology. Additionally, BIRAC has emerged as a critical interface between public and private sectors. It facilitates targeted funding, mentorship, and industry-academia partnerships. Consequently, the number of biotech startups in India has skyrocketed from just 50 to over 11,800 today.
Moreover, the launch of the BioE3 Policy marks a significant strategic shift. This policy focuses on economy, environment, and employment by promoting sustainable biomanufacturing. For instance, the government is setting up biofoundries and Bio-AI hubs to support deep-tech innovation. Therefore, these initiatives ensure that India remains a global leader in precision medicine and biopharmaceuticals.
India is now on a clear path to becoming the world’s third-largest economy. The country aims to reach a $300 billion bioeconomy by 2030. To achieve this, the government is utilizing a ₹1 lakh crore Research, Development, and Innovation (RDI) Fund. This fund supports high-risk scientific innovation and clinical research. Although challenges like the COVID-19 pandemic existed, the sector demonstrated remarkable resilience. Specifically, the biopharma segment remains the largest contributor, accounting for 35% of the total bioeconomy value.
Q1: What is the current value of India's bioeconomy?
As of March 2026, India's bioeconomy is valued at approximately $195.3 billion, having grown from $10 billion in 2014.
Q2: What is the role of BIRAC in this growth?
BIRAC acts as a model institution that bridges the gap between academia and industry. It provides risk capital, infrastructure support, and mentorship to over 11,000 startups.
Q3: What is the target for India's biotech sector by 2030?
The Indian government has set an ambitious target to reach a $300 billion bioeconomy by the year 2030.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
India’s biotech sector surged to $195 billion, driven by BIRAC, over 11,800 startups, and strategic policies like BioE3, aiming for $300 billion by 2030....
5 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
